Back to News
Market Impact: 0.12
Epitel Adds Proven Medtech Leader James Reinstein to Board As Company Enters Next Stage of Growth
Source: Business Wire
Management & GovernanceHealthcare & Biotech
Epitel appointed James Reinstein to its board as the epilepsy-focused medtech company expands its REMI® platform and enters its next growth phase. The company cited Reinstein's medical-technology and epilepsy experience, but disclosed no financial metrics, commercial milestones, or guidance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Anthropic's IPO push includes a big bet on life sciences
- The big questions remaining after Anthropic’s blockbuster IPO prospectus
- UnitedHealth is finally getting its act together. I'm buying into the turnaround
- Illumina CEO on Q3 Results and Business Outlook
- Swiss Firms Plan Investment Boost in China Drug, Finance Sectors
- Bernstein SocGen raises Eli Lilly stock price target on strong Q3 beat
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- Which AI Investment Research Platforms Are SOC 2 Certified?
- State of M&A and Private Markets, June 2026: A $4.9 Trillion Rebound, Underwritten on Money That Never Got Cheaper